Impact of SARS-CoV-2 (COVID-19) Infection, Treated in Ambulatory Care, on Long-term Quality of Life in a Parisian Military Population

Study Overview
=================
Brief Summary
-----------------
In April 2020, a meta-analysis on the long-term sequelae of respiratory syndromes related to seasonal coronaviruses (SARS and MERS) showed a significant alteration in quality of life, with in particular a decrease in physical and emotional capacities and a deterioration of social life. An improvement of the quality of life is evidenced after 6 months but without reaching the level usually observed in healthy people. The impact of SARS-CoV-2 infection on quality of life can be explained by the persistence of pleomorphic symptoms in the medium to long term. In the military population, the majority of SARS-CoV-2 cases present minor to moderate forms of the disease. Military personnel have living conditions that differ from those of the general population, in particular because of their geographic mobility, which may be responsible for isolation from the family. This isolation can be regular (we speak of geographical celibacy when the soldier is posted in a geographical area far from the family unit) and/or occasional, during missions on the national territory or outside. This singularity justifies a study on the impact of SARS-CoV-2 (COVID-19) infection on the quality of life in this specific population.

Official Title
-----------------
Impact of SARS-CoV-2 (COVID-19) Infection, Treated in Ambulatory Care, on Long-term Quality of Life in a Parisian Military Population

Conditions
-----------------
SARS-CoV2 Infection, Covid19

Intervention / Treatment
-----------------
* Other: Questionnaires COVID+
* Other: Questionnaires COVID-


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Military personnel COVID+: diagnosed with COVID-19 and managed in ambulatory care since March 14th, 2020 COVID-: not having been infected with SARS-CoV-2 Exclusion Criteria: Hospitalized for COVID-19 Having received a treatment against COVID-19 (other than paracetamol)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID+<br>Questionnaires on COVID-19 symptomatology and quality of life | Other: Questionnaires COVID+<br>* 1 questionnaire on COVID-19 symptomatology and quality of life 12 months after COVID-19 first symptoms 1 questionnaire on quality of life 18 months after COVID-19 first symptoms<br>|
| COVID-<br>Questionnaires on quality of life | Other: Questionnaires COVID-<br>* 1 questionnaire on quality of life at enrollment 1 questionnaire on quality of life 6 months after enrollment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Long-term quality of life (mental component) | Mental Component Score (MCS) of the SF-36 questionnaire. The MCS ranges from 0 (bad quality of life) to 100 (good quality of life). | 18 months after COVID-19 first symptoms | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Long-term quality of life (physical component) | Physical Component Score (PCS) of the SF-36 questionnaire. The PCS ranges from 0 (bad quality of life) to 100 (good quality of life). | 18 months after COVID-19 first symptoms | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Quality of life